Moderna Therapeutics, a biotech company has shipped the first batches of its COVID-19 vaccines called mRNA-1273 and its clinical trial has been commenced.

The press releases issued by the Moderna Therapeutics and the NIH news confirms the shipment and trial of the first batches of the COVID-19 vaccines.

The press releases issued by the Moderna Therapeutics and the NIH news confirms the shipment and trial of the first batches of the COVID-19 vaccines.The press release issued by the Moderna Therapeutics on 24 February 2020 mentioned that the first batch of mRNA-1273, the company’s vaccine against the novel coronavirus for human use, has been shipped to the United States’ National Institute of Allergy and Infectious Diseases (NIAID) which is a part of the National Institutes of Health (NIH).

The National Institutes of Health (NIH) on 16 March 2020, in its news release has said that Phase 1 clinical trial of the mRNA-1273 vaccine has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle and the open-label trial will enrol 45 healthy adult volunteers aged between 18 to 55 years for approximately over 6 weeks. The first participant had received the investigational vaccine.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.